UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% Improves Morning (AM) Ocular Redness Scores in a Placebo-Controlled Environmental Study of Seasonal Allergic Rhinoconjunctivitis (SAR)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB190-AB190

2012

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2011, Vol.127 (2), p.AB257-AB257

2011

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB256-AB256

2011

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB255-AB255

2011

Volltextzugriff (PDF)

BepreveTM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

BepreveTM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

BepreveTM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

The Ocular Comfort and Safety of the Novel Anti-Histamine Bepotastine Besilate Ophthalmic Solution 1.5% in a Healthy Pediatric Population

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S50-S50

2009

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S57-S57

2009

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S57-S57

2009

Volltextzugriff (PDF)

Bepotastine Besilate Ophthalmic Solution 1.0% Provides Rapid Relief of Rhinorrhea, Total Non-Ocular Symptoms, Tearing, and Ciliary and Episcleral Hyperemia Following Dosing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S57-S57

2009

Volltextzugriff (PDF)

Fast maximum power point control of current-fed DC-DC converter for photovoltaic arrays

Electronics letters, 2001-01, Vol.37 (1), p.5-6

2001

Volltextzugriff (PDF)

MIMO-OFDM-based DVB-H systems: a hardware design for a PAPR reduction technique

IEEE transactions on consumer electronics, 2006-11, Vol.52 (4), p.1201-1206

2006

Volltextzugriff (PDF)

Development of a photovoltaic array model for use in power-electronics simulation studies

IEE proceedings. Electric power applications, 1999, Vol.146 (2), p.193

1999

Volltextzugriff (PDF)

Bepreve TM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

Bepreve TM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

Bepreve TM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Journal of allergy and clinical immunology, 2010, Vol.125 (2), p.AB38-AB38

2010

Volltextzugriff (PDF)

Controller arrangement for boost converter systems sourced from solar photovoltaic arrays or other maximum power sources

IEE proceedings. Electric power applications, 2000, Vol.147 (1), p.15

2000

Volltextzugriff (PDF)

The effect of temperature on the fatty acids and isozymes of a psychrotrophic and two mesophilic species of Xenorhabdus, a bacterial symbiont of entomopathogenic nematodes

Canadian journal of microbiology, 2001-05, Vol.47 (5), p.382-391

2001

Volltextzugriff (PDF)

Phenotypic characterization of the Xenorhabdus bacterial symbiont of a Texas strain of the entomopathogenic nematode Steinernema riobrave, and characterization of the Xenorhabdus bovienii bacterial symbiont of a Newfoundland strain of Steinernema feltiae

Canadian journal of microbiology, 2000-07, Vol.46 (7), p.618-622

2000

Volltextzugriff (PDF)

Cross Reactivity of Non-Enteropathogenic Serogroups with Polyvalent Antiserum While Screening for Enteropathogenic Escherichia coli in Codfish and Shellfish

Canadian Institute of Food Science and Technology journal, 1988-02, Vol.21 (1), p.72-75

1988

Volltextzugriff (PDF)

Pantoea agglomerans is the etiological agent for black spot necrosis on beach peas

Canadian journal of microbiology, 1996-12, Vol.42 (12), p.1252-1257

1996

Volltextzugriff (PDF)

The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin

Prostaglandins, leukotrienes and essential fatty acids, 1993-07, Vol.49 (1), p.515-520

1993

Volltextzugriff (PDF)

Photovoltaic converter system suitable for use in small scale stand-alone or grid connected applications

IEE proceedings. Electric power applications, 2000-11, Vol.147 (6), p.535

2000

Volltextzugriff (PDF)

Development of a model for photovoltaic arrays suitable for use in simulation studies of solar energy conversion systems

6th International Conference on Power Electronics and Variable Speed Drives, 1996, p.69-74

1996

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(14)
Allergy And Immunology
(11)
Biological And Medical Sciences
(10)
Technology
(8)
Drug Therapy
(7)
Engineering
(7)
Engineering, Electrical & Electronic
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Clinical Trials
(6)
Biochemistry & Molecular Biology
(5)
Microbiology
(5)
Animals
(4)
Biotechnology & Applied Microbiology
(4)
Fda Approval
(4)
Female
(4)
Humans
(4)
Immunology
(4)
Laboratories
(4)
Male
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% Improves Morning (AM) Ocular Redness Scores in a Placebo-Controlled Environmental Study of Seasonal Allergic Rhinoconjunctivitis (SAR)

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

BepreveTM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

BepreveTM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

BepreveTM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

The Ocular Comfort and Safety of the Novel Anti-Histamine Bepotastine Besilate Ophthalmic Solution 1.5% in a Healthy Pediatric Population

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.0% Provides Rapid Relief of Rhinorrhea, Total Non-Ocular Symptoms, Tearing, and Ciliary and Episcleral Hyperemia Following Dosing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Fast maximum power point control of current-fed DC-DC converter for photovoltaic arrays

MIMO-OFDM-based DVB-H systems: a hardware design for a PAPR reduction technique

Development of a photovoltaic array model for use in power-electronics simulation studies

Bepreve TM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Bepreve TM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Bepreve TM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

Controller arrangement for boost converter systems sourced from solar photovoltaic arrays or other maximum power sources

The effect of temperature on the fatty acids and isozymes of a psychrotrophic and two mesophilic species of Xenorhabdus, a bacterial symbiont of entomopathogenic nematodes

Phenotypic characterization of the Xenorhabdus bacterial symbiont of a Texas strain of the entomopathogenic nematode Steinernema riobrave, and characterization of the Xenorhabdus bovienii bacterial symbiont of a Newfoundland strain of Steinernema feltiae

Cross Reactivity of Non-Enteropathogenic Serogroups with Polyvalent Antiserum While Screening for Enteropathogenic Escherichia coli in Codfish and Shellfish

Pantoea agglomerans is the etiological agent for black spot necrosis on beach peas

The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin

Photovoltaic converter system suitable for use in small scale stand-alone or grid connected applications

Development of a model for photovoltaic arrays suitable for use in simulation studies of solar energy conversion systems

Suchergebnisse filtern